UPDATE: Correction: Moderna (MRNA) PT Raised to $353 at Brookline Capital Markets, Following Clinical Business Update

August 2, 2021 1:24 PM EDT
Get Alerts MRNA Hot Sheet
Price: $430.14 -5.38%

Rating Summary:
    6 Buy, 8 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 17 | Down: 5 | New: 36
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
(Updated - August 2, 2021 1:36 PM EDT)

(Updated to correct target prices, previously reported 224 --> 352)

Brookline Capital Markets analyst Leah Rush Cann raised the price target on Moderna (NASDAQ: MRNA) to $353.00 (from $352.00) while maintaining a Buy rating.

Analyst comments: "We believe this is an important development for Moderna, to initiate this phase I study with subcutaneously administered mRNA candidate addressing autoimmune disease. We currently estimate, that if approved, mRNA-6231 could enter the market in 2029, and conservatively estimate it will achieve and 1.0% market penetration in this setting in 2030, resulting in worldwide estimated sales for mRNA-6231 of $1.45 billion in 2030. We estimate meaningful impact coult result post-2030, based on the target market opportunity presented by autoimmune disease market.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change